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The active enhancer network operated
by liganded RXR supports angiogenic
activity in macrophages
Bence Daniel,1,8 Gergely Nagy,1,8 Nasun Hah,2 Attila Horvath,1 Zsolt Czimmerer,1 Szilard Poliska,1
Tibor Gyuris,1 Jiri Keirsse,3,4 Conny Gysemans,5 Jo A. Van Ginderachter,3,4 Balint L. Balint,1
Ronald M. Evans,2 Endre Barta,6 and Laszlo Nagy1,6,7,9
1Department of Biochemistry and Molecular Biology, University of Debrecen, Debrecen H-4032, Hungary; 2The Salk Institute
for Biological Studies, San Diego, California 92037, USA; 3Myeloid Cell Immunology Laboratory, Vlaams Instituut voor
Biotechnologie (VIB), Brussels B-1050, Belgium; 4Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel,
Brussels B-1050, Belgium; 5Laboratory of Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven
B-3000, Belgium; 6MTA-DE Lendu¨let Immunogenomics Research Group, University of Debrecen, Debrecen H-4032, Hungary
RXR signaling is predicted to have a major impact in macrophages, but neither the biological consequence nor the
genomic basis of its ligand activation is known. Comprehensive genome-wide studies were carried out to map
liganded RXR-mediated transcriptional changes, active binding sites, and cistromic interactions in the context of
the macrophage genome architecture. The macrophage RXR cistrome has 5200 genomic binding sites, which are
not impacted by ligand. Active enhancers are characterized by PU.1 binding, an increase of enhancer RNA, and
P300 recruitment. Using these features, 387 liganded RXR-bound enhancers were linked to 226 genes, which
predominantly reside in CTCF/cohesin-limited functional domains. These findings were molecularly validated
using chromosome conformation capture (3C) and 3C combined with sequencing (3C-seq), and we show that
selected long-range enhancers communicate with promoters via stable or RXR-induced loops and that some of the
enhancers interact with each other, forming an interchromosomal network. A set of angiogenic genes, including
Vegfa, has liganded RXR-controlled enhancers and provides the macrophage with a novel inducible program.
[Keywords: RXR; macrophage; transcription; enhancer; angiogenesis]
Supplemental material is available for this article.
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RXR is an unusual and somewhat neglected member of
the nuclear receptor superfamily because it is still not
known how this receptor interacts with the genome and
regulates gene expression upon ligand activation. It is
expressed in every cell type and is required for postnatal
life in mice (Mangelsdorf et al. 1992; for review, see Szanto
et al. 2004). Its presumed main molecular function is to
regulate the activity of a dozen or so nuclear receptors.
There is also evidence that it can form homodimers and/or
have heterodimer-independent signaling capacity (Zhang
et al. 1992; Szeles et al. 2010). A key concept regarding RXR
signaling is the permissiveness/nonpermissiveness mutu-
ally exclusive dual paradigm. According to this, in certain
heterodimers such as RXR:PPAR and RXR:LXR, ligand
activation of RXR results in transcriptional activation;
hence, these are permissive heterodimers, while in other
heterodimers such as RAR:RXR, TR:RXR, and VDR:RXR,
RXR is suppressed or ‘‘subordinated,’’ and therefore these
so-called nonpermissive heterodimers cannot be activated
from the RXR side (Germain et al. 2002). Therefore, the
activation of all permissive heterodimers present in a par-
ticular cell type might lead to pleiotropic gene activation
and engagement of potentially conflicting pathways.
The existence of pleiotropy, the role of RXR activation
of permissive heterodimers, and the presence and activity
of RXR homodimers have been debated and remain
largely unresolved.
The fact that certain natural lipids—such as 9-cis
retinoic acid (RA), docosahexanoic acid, and phytanic
acid—are able to activate RXR gives further support to
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the biological role of RXR activation in vivo (for a review,
see Szanto et al. 2004). There are also potent and selective
synthetic compounds such as bexarotone (LG10069) and
LG100268 (LG268) (Boehm et al. 1994, 1995) that have
been used to dissect the role of the receptor in various
biological systems and/or used in therapies. In macro-
phages, there are several heterodimeric receptors with key
cellular roles, such as PPARg regulating oxLDL uptake and
processing, LXR regulating cholesterol efflux and immune
function, and NR4A1 (NUR77) regulating inflammatory
response. These heterodimeric receptors have been linked
to the development of atherosclerosis and also immune
function and provide means to reprogrammacrophages (for
reviews, see Calkin and Tontonoz 2012; Nagy et al. 2012).
Therefore, it is important to understand how activation of
RXRcontributes to these pathways and potentially tonovel
ones and regulates gene expression in this cell type.
A key issue in understanding any signal-specific tran-
scription factor is the determination of the genomic sites
to which it binds and to link those to the target tran-
scripts. Recent advances in genome-wide approaches
allow global assessment of histone modifications and
transcription factor genomic binding sites (Ostuni et al.
2013). It is done using microarrays or RNA sequencing
(RNA-seq) (Mortazavi et al. 2008). However, the temporal
changes in steady-statemRNA levels diverge from changes
in transcription; hence, simply determining steady-state
mRNA levels will not allow easy identification of primary
transcriptional events and will not separate those from
secondary and tertiary ones (Bhatt et al. 2012). The de-
velopment of genome-wide localization studies, primarily
ChIP-seq (chromatin immunoprecipitation [ChIP] com-
bined with deep sequencing) approaches, aided the de-
termination of transcription factor-binding sites within
the context of the chromatin structure on the genomic
scale. Such genome-wide studies suggest that enhancers
and promoters exhibit distinct chromatin ‘‘signatures.’’
The characteristic signature for enhancers consists of
monomethylation of histone H3 Lys4 (H3K4me1), acetyla-
tion of histones (H3K9ac and H3K27ac), and binding of the
acetyltransferase P300 (Heintzman et al. 2007; Koch et al.
2007; Visel et al. 2009).
In spite of all these developments, the reliable linking
of activated enhancers to the regulated gene is still not
solved, partly due to the lack of markers linking the ge-
nomic binding site to the regulated transcript and partly
due to the potentially large distances between the en-
hancer and the regulated gene. Moreover, the identifi-
cation of enhancers is even more cumbersome, if not
impossible, in the case of signal-dependent transcription
factors (such as RXR), which may constitutively occupy
genomic sites. In our studies, we tried to solve these
issues by combining RNA-seq, ChIP-seq, GRO-seq (global
run-on sequencing), and 3C-seq (chromosome conforma-
tion capture [3C] combined with sequencing) in a highly
integrated way to unravel the mechanism of RXR-induced
transcriptional events in mouse bone marrow-derived
macrophages (BMDMs) and, as the result of the process,
discovered and validated a novel biological activity pro-
moted by the receptor.
Results
The transcriptional consequences of RXR activation
in murine macrophages
We set out to systematically determine the genomic
events following RXR ligand activation in BMDMs (Fig.
1A). The synthetic and selective RXR ligand LG268 was
applied throughout the studies in a 100 nM concentration.
We determined the changing transcripts by RNA-seq
(analyzed by the pipeline shown in Supplemental Fig.
S1A) and found that selective activation of RXR affects
the steady-state mRNA levels of hundreds of genes, as
expected. A hierarchical clustering of the top 200 changing
genes as a time course is shown in Figure 1B. In order to
identify primary RXR targets, we embarked on analyses to
determine both the genomic binding events of RXR (RXR
cistrome) and the enhancers responsible for the transcrip-
tional changes.
Determination of the RXR, PU.1, and P300 cistromes
and mapping active histone marks in BMDMs,
the effect of ligand
By carrying out ChIP-seq experiments, we determined
the cistromes of RXR in the absence and presence of its
ligand, LG268, and its relationship to the lineage-specific
transcription factor PU.1 and the cofactor P300 along
with a marker of transcription initiation, H3K4me3, and
active histone marks, H3K27ac, H4ac, and H3K4me2,
using the algorithm depicted in Supplemental Figure S1B.
We determined ;5200 RXR genomic binding regions.
Importantly, this cistrome is not impacted greatly by
ligand treatment in 60 min. PU.1 occupied the highest
number of peaks (;30,000), with only a minimal rear-
rangement upon ligand exposure (Supplemental Fig. S1C).
Although the number of RXR-binding regions does not
changemuch upon ligand exposure, peaks gain;30%more
reads, suggesting that RXR enrichment on the genomic
regions is enhanced (Fig. 1C). We confirmed these observa-
tions byChIP and real-time quantitative PCR (RT-qPCR) on
binding regions of known directly regulated genes (Fig. 1D;
Nagy et al. 1996; Kersten et al. 2000; Repa et al. 2000).
Intriguingly, P300 binding follows the genome-wide RXR
enrichment, suggesting that P300 is likely to be recruited to
the genome upon RXR activation (Supplemental Fig. S1C).
The motif rank order under the detected RXR peaks
reported that PU.1 had the most enriched motif, followed
by various combinations of repeats, including DR1 and
DR4, of the nuclear receptor-binding (half) site. In addi-
tion, with somewhat lower abundance, two other mac-
rophage-associated motifs were also detected: C/EBP and
AP-1 (Fig. 1E). As far as the genomic distribution of the
detected peaks is concerned,;90%were found outside of
the potentially directly regulated 823 genes identified by
RNA-seq experiments (i.e., not within 10 kb of their
transcription start sites [TSSs]) (Fig. 1F), suggesting that
linking binding sites to regulated genes based simply on
proximity will be difficult.
Next, we continued to interrogate the cistromes of
PU.1, RXR, and P300 in the ligand-activated state. The
Liganded RXR’s genomic action
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RXR peaks overlap with both PU.1 and P300 to a large
extent and show increased acetylation (Fig. 2A,B). Global
analyses show that ligand activation of RXR leads to P300
recruitment (Fig. 2B,C). These changes could be validated
by ChIP-RT-qPCR (Fig. 2C). Importantly, global P300
binding and recruitment could be detected and confirmed
at >400 sites using three biological replicates, and no
decrease could be observed (Supplemental Fig. S2A). As
far as active histone marks are concerned, H4 acetylation
and H3K4 dimethylation are increasing, while H3K27
acetylation remains largely unchanged upon ligand acti-
vation on the RXR-bound genomic regions (Fig. 2D).
Next, we sought to determine whether some of the
potential partner ligands had a detectable effect on the
RXR cistrome. Therefore, we determined the RXR cis-
tromes in the presence of a synthetic LXR (GW3965) or
PPARg (RSG) ligand as the activators of the two major
suspected heterodimeric partners present in macrophages.
We found that neither ligand had a statistically significant
effect on RXR’s genome-wide distribution and/or affinity,
applying a <0.1 false discovery rate (FDR) threshold (Fig.
2E). Finally, we wanted to evaluate the possibility of
whether an endogenous RXR ligand is masking a ligand-
induced (re)distribution of the receptor. We reasoned that
eliminating the effect of a presumed endogenous ligand by
an RXR antagonist (LG1208) would reveal the true unli-
ganded RXR cistrome. However, as shown in Figure 2E,
the RXR cistrome does not change upon antagonist treat-
ment either. These findings were confirmed using RT-
qPCR (Supplemental Fig. S2B). These data suggest that the
Figure 1. Mapping the transcriptional consequences of selective activation of RXR in murine macrophages. (A) The scheme of
macrophage differentiation and the chemical structure of LG268. (B) Heat map representation of the expression of genes regulated by
LG268. Differentiated macrophages were treated with 100 nM LG268 for the indicated time, and total RNAwas subjected to RNA-seq
gene expression analysis (Supplemental Fig. S1A). Biological replicates had at least 70 million reads each. The presented gene set was
filtered at FDR < 0.1 and a more than twofold change. (C) Average read distribution of RXR peaks in the presence or absence of LG268.
ChIP-seq data were analyzed as shown in Supplemental Figure S1B (peaks were predicted by MACS2, and the consensus of the 2 3 2
replicates was determined by DiffBind); the histogram was generated by HOMER. (#) Normalized throughout the study. (D) RXR
binding on the indicated individual enhancers confirmed using ChIP-RT-qPCR. Macrophages were treated with 100 nM LG268 for 1 h.
The mean and 6SD of triplicate determinations are shown. (E) De novo and targeted (asterisk) identification of motifs under RXR peaks
from ChIP-seq data using HOMER. ‘‘Target %’’ refers to the ratio of the peaks having the given motif, and ‘‘Bg %’’ refers to the ratio of
a random background as described in the Supplemental Material. (F) The genome-wide distribution of RXR peaks relative to the TSS of
the closest regulated genes identified by RNA-seq (P < 0.05; n = 823).
Daniel et al.
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RXR cistrome is not changing upon short-term ligand
activation and that the RXR selective ligand only increases
the receptor’s enrichment at its predetermined binding
sites, which typically bind PU.1 and recruit P300. Impor-
tantly, the dominant ligands of relevant permissive hetero-
dimers such as PPARg or LXR do not appear to have an
effect on either distribution or affinity.
Determination of liganded RXR regulated nascent
RNA production
The merging of the ChIP-seq and RNA-seq data sets
proved to be insufficient to reliably identify the network
of primary regulated genes and their enhancers. This is
due to the fact that the physical location of the bound
transcription factor cannot be linked to the regulated
gene. Almost 90% of the RXR peaks are located outside
of the 10-kb region upstream of the TSS of the closest
regulated gene (Fig. 1F), which is in good correlation with
others’ observations (Thurman et al. 2012).
We reasoned that in order to link a liganded RXR-
occupied enhancer to the corresponding regulated
gene, one needs a high-resolution method, which can
provide dynamic temporal information about transcrip-
tion. The recently recognized fact that nascent RNA
production can be detected on both the regulated gene
Figure 2. The cistromic interactions of RXR, PU.1, P300, and active histone marks. (A) The intersection of cistromes as assessed by
number of overlapping peaks is represented as a Venn diagram of RXR and PU.1. (B) Heat map representation of RXR, P300, H3K4me2,
H3K27ac, and H4ac occupancies in 3-kb windows around the summit of the RXR peaks in the presence or absence of LG268. Read
distribution was determined by HOMER, clustering was done by Gene Cluster 3.0 using centered correlation similarity metric with single
linkage clustering method, and heat maps were created by Java TreeView in log2 scale. (C) Read distribution of P300 on RXR peaks in the
presence or absence of LG268. P300 binding was confirmed on the indicated individual enhancers using ChIP-RT-qPCR.Macrophageswere
treatedwith 100 nMLG268 for 1 h. Themean and6SDof three biological replicates are shown. Asterisk represents significant difference at
P < 0.05; n = 3. (D) Average read distribution of the indicated active histone marks on RXR peaks in the presence or absence of LG268
determined by HOMER. (E) RXR enrichments of the significantly changing peaks in the presence of the indicated ligands. Cistrome was
determined in the presence or absence of LG268, and the log2-normalized read numbers of the significantly changing peaks were plotted by
DiffBind. The number of changing peaks and the statistical stringency applied is indicated below each plot.
Liganded RXR’s genomic action
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and the enhancer offered a plausible solution (Wang
et al. 2011).
Therefore, we decided to detect the dynamics of na-
scent RNA production using GRO-seq. As shown in
Figure 3A, we carried out a time-course experiment to
determine the sites and dynamics of nascent RNA pro-
duction upon LG268 activation, a typical example of
which is shown for Abca1 induction in Figure 3B. Impor-
tantly, we noticed the presence and induction of nascent
RNA transcripts at sites of enhancers, eTranscripts, and
also short divergent transcripts (Core et al. 2008). We
collectively call these enhancer RNAs (eRNAs). Nota-
bly, if one aligns the detected GRO-seq activities with
cistromic data, it is easy to recognize that short tran-
scripts overlapwith transcription factor-bound regions—in
our case, PU.1, RXR, and P300 (Fig. 3C; Supplemen-
tal Fig. S3A). A comprehensive analysis of GRO-seq
active regions, including gene transcript and eRNA
calling, was carried out by a unique algorithm (Supple-
mental Fig. S3B). We determined that ;20% of the
mouse genome is transcribed (with at least 0.006 RPKM
[reads per kilobase per millionmapped reads] expression)
in this macrophage cell type and identified 10,586
known genes also marked by H3K4me3 and, all together,
25,560 transcripts, which include eRNAs and other
noncoding RNAs as well (Supplemental Fig. S3C). Im-
portantly, we found 51,657 GRO-seq divergent sites
(>0.2 RPKM expressed) characterized by divergent tran-
scription with a distance <300 bases between the 59 ends
of the transcripts on the two strands. These sites do not
Figure 3. Determination of nascent RNA production upon activation of RXR. (A) The scheme of GRO-seq experiments. Cells were
treated for the indicated time periods and collected, nuclei were isolated, and run-on sequencing was performed. (B) The detected
induction of GRO-seq activity on the Abca1 locus. Nascent RNA produced around the Abca1 locus is shown. Strand-specific coverage
is represented by red and blue. (C) Genome browser view of the merge of GRO-seq, and ChIP-seq activity/peaks on the Abca1 locus.
Overlaps of PU.1, RXR, and P300 binding with divergent sites (GRO-seq-positive) are indicated with arrows. (D) Comparison of mRNA
production dynamics using nascent (GRO-seq) and steady-state (RNA-seq and RT-qPCR) RNA determinations. Macrophages were
treated with LG268 for the indicated time period, and specific gene expression was detected with the indicated method. A
representative set of experiments is shown. Expression was normalized to the 0 time point.
Daniel et al.
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necessarily show elongation, just initiation irrespective
of transcribed genes and other longer transcripts. One
could reasonably assume that this set of genomic regions
contains all active promoters and enhancers. Using this
approach, we determined changing (induced/repressed)
gene transcripts and eRNAs as well. If one plots the
changing levels of nascent RNA production of already
established direct target genes, the dynamics of the
changes are indicative of an immediate induction (Fig.
3D). This also allows easy identification of additional
direct targets.
These data further reinforced the notion that the
dynamically changing nascent RNA landscape provides
clues about direct transcriptional regulation specific for
RXR liganding. Furthermore, this allowed us to generate
a list of genes most likely being directly regulated by
liganded RXR (Supplemental Table S1).
As far as the active enhancers are concerned, we
classified the identified ;5200 RXR-binding sites into
two categories using an algorithm (pipeline depicted in
Supplemental Fig. S4A): (1) enhancers that overlap with
a GRO-seq-positive region (divergent site; 2781) and (2)
enhancers that do not overlap with GRO-seq activity
(2425), as shown in Figure 4, A and B). This classification
showed an enrichment of RXR peaks within the proxim-
ity of the closest TSS (<10 kb from the TSS), suggesting
that our assumption was likely correct and that we were
identifying the functional/active binding regions and
efficiently separating those from the silent/nonactive/
parking ones. The distribution of GRO-seq-positive and
GRO-seq-negative RXR-bound regions relative to the
nearest TSS shows a bias toward upstream regions in cases
of the positive ones. Most interestingly, the enriched
motif distribution under these peaks also showed charac-
teristic differences. The GRO-seq-positive RXR sites
showed an enrichment for DR1 and DR4 (binding sites of
RXR:PPAR and RXR:LXR heterodimers, respectively) as
well as AP-1 sites when compared with the GRO-seq-
negative sites (Fig. 4B).
GRO-seq-positive RXR-binding sites are characterized
by an increased H3K27ac, H4ac, and also H3K4me2
histone marks when compared with negative ones (Fig.
4C,D). These provided further support to the notion that
these sites are indeed functionally distinct and likely
represent active enhancers.
A closer look at the up-regulated GRO-seq-positive
regions revealed that those that overlap with RXR peaks
overlap with a significant fraction of PU.1 regions as well
(Fig. 5A, top). The regions of down-regulated GRO-seq
activity have much fewer RXR peaks but show overlap
with PU.1 regions to a larger degree as well (Fig. 5A,
bottom). These latter analyses showed that there are very
few liganded RXR-occupied negative binding sites or
silencers, suggesting also that liganded RXR is predomi-
nantly a transcriptional activator. Next, we matched up
the divergent GRO-seq sites with RXR sites (Fig. 5B;
Supplemental Fig. S5A). The identified 51,657 divergent
GRO-seq sites likely contain all TSSs, short divergent
transcripts, and eRNAs. More than 3300 of these change
upon RXR ligand activation, and 718 overlap with RXR-
binding sites as well (Fig. 5A,C). We identified 252
regulated genes to which we could assign 414 RXR-bound
regions, 387 enhancers, and 27 silencers using the criteria
set by us (Fig. 5B,C; Supplemental Fig. S4A).
The distribution of the various motifs within these
potentially active enhancers show that ;50% can be
classified as a nuclear receptor-binding site repeat, an-
other 20% is PU.1 only, and a quarter is other or unknown
(Fig. 5D). The number of enhancers per gene ranges from
one to nine (Fig. 5E). The distribution of these putative
enhancers relative to the TSS is fairly symmetrical, and
they span long distances, with only 16.54% found within
10 kb upstream of the TSS (Fig. 5F). The identified 387
enhancers have a pronounced increase in RXR occu-
pancy, P300 recruitment, and H4ac, while H3K4me2
and H3K27ac are not different upon ligand treatment
(Supplemental Fig. S4B).
Taking these together, we (1) uncovered the core active
enhancer network operated by liganded RXR; (2) se-
parated these sites from nonfunctional, silent/parking
RXR-binding sites; and (3) paired the active enhancer
network with the regulated genes using a set of criteria.
Functional validation of novel distant and long-range
enhancers
Before we embarked on molecular validation of the
enhancers, we intended to assess the contribution of the
activated partner receptors to the induction of various
RXR-regulated genes and eRNAs also. Therefore, we de-
termined the induction of steady-state RNA levels of
selected genes. We found that Vegfa and Hbegf were
induced primarily by RXR liganding with some activity
by RAR, Tgm2 and Ccl6 were both induced by RXR and
RAR liganding, Abcg1 was induced by RXR and LXR, and
Angptl4 was induced by the RXR and PPARg ligands
(Supplemental Fig. S5).
Interestingly, primarily RXR-induced eRNA produc-
tion could be detected on an enhancer assigned to Vegfa
or Tgm2, while an enhancer of Abcg1 also showed robust
LXR ligand activation, as expected (Fig. 5G). These data
suggested that the eRNAs can be easily validated and
show ligand induction similar to the regulated genes and
therefore most likely are linked.
For functional validation, we chose 45 newly identified
regulatory regions assigned to 23 genes (Supplemental
Table S1). We selected 30 distant enhancers (>10 kb from
the TSS), which earlier studies performing traditional
enhancer analyses (Schwartz et al. 2000) would likely
have missed, including one of ours (Nagy et al. 1996). In
addition, we sought to validate 15 more proximal en-
hancers (<10 kb from the TSS).
Next, we cloned the 45 putative cis-regulatory ele-
ments (35 enhancers and 10 silencers) in front of a lucif-
erase reporter gene and measured their transcriptional
activity in COS1 cells in the presence of combinations of
receptors and ligands. We clustered the enhancers based
on the induction patterns obtained in the transient trans-
fection-based reporter system, which is detailed in the
Supplemental Material (Supplemental Fig. S6). These
Liganded RXR’s genomic action
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analyses show that the identified and tested enhancers
are RXR-specific enhancers but also complex and very
versatile, allowing combinatorial and context-dependent
regulation of the genes by distinct dimers. The context is
determined by the receptor expression profile and prob-
ably also lineage-specific transcription factors and co-
factors. In addition, a single gene is likely to have distinct
types of enhancers.
Figure 4. Classification of RXR-binding sites based on GRO-seq activity. (A, top left) Distribution of the (GRO-seq+) divergent sites
detected based on genome-wide localization relative to the closest expressed transcripts (>3 kb including 39 overhang) determined by
GRO-seq. Distribution of all RXR sites (top right), the RXR sites overlapping with GRO-seq activity (bottom left), and the RXR sites not
overlapping with GRO-seq activity (bottom right) relative to the expressed transcripts. (B) Distribution of GRO-seq-positive (blue) and
GRO-seq-negative (red) RXR peaks compared with the TSSs of the closest expressed transcripts (defined as in A). Columns represent the
peak number of the 1-kb distance bins. (Insert) De novo and targeted (black asterisk) identification of motifs under GRO-seq-positive
(left side) and GRO-seq-negative (right side) RXR peaks determined using HOMER. Differentially represented motifs are marked by red
asterisks. ‘‘Target %’’ refers to the ratio of the peaks having the given motif, and ‘‘Bg %’’ refers to the ratio of a random background as
described in the Supplemental Material. (C) Heat map representation of RXR, P300, H3K4me2, H3K27ac, and H4ac occupancies in 3-kb
windows around the summit of the GRO-seq-positive and GRO-seq-negative RXR peaks in the presence or absence of LG268. Read
distribution was determined by HOMER, clustering was done by Gene Cluster 3.0 using centered correlation similarity metric with
single linkage clustering method, and heat maps were created by Java TreeView in log2 scale. (D) Read distribution of the indicated
histone marks relative to the GRO-seq-positive and GRO-seq-negative RXR cistromes determined by HOMER.
Daniel et al.
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Figure 5. Identification of RXR-regulated enhancers and linking those to regulated genes. (A) Overlap of sites of changing GRO-seq
activity and cistromes of liganded RXR and PU.1: increasing GRO-seq activity (top) and decreasing GRO-seq activity (bottom). (B)
Scheme of annotation criteria on the Abca1 locus. This includes increased (or decreased) nascent transcript production of a gene and
increased (or decreased) divergent transcription of a region occupied by RXR. (C) Flow of annotation of GRO-seq-positive RXR-binding
regions with changing enhancer transcription to the closest gene with changing expression. See also Supplemental Figure S4A.
(D) Motif distribution of the annotated 387 RXR-bound enhancers determined by HOMER and fuzznuc as described in the
Supplemental Material. Note that additional PU.1 sites can be found in conjunction with other motifs, which are not included here.
(E) Distribution of the number of enhancers assigned to the closest gene; the Y-axis shows the number of genes having the number of
enhancers (X-axis). (F) Distribution of enhancers relative to TSSs of the identified directly regulated genes. (G) RT-qPCR analysis of
Vegfa, Abcg1, and Tgm2 eRNAs. Differentiated macrophages were treated with LG268, RSG, GW3965, and AM580 for 1 h, and eRNAs
were determined. Data represent mean and 6SD, with expression normalized to Rplp0.
Liganded RXR’s genomic action
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The genome architectural context of RXR-regulated
gene expression
Once we determined the RXR-regulated genes and linked
at least a subset of them to their enhancers (some of them
are long-range ones), we wanted to get some insight into
whether these regulatory units are confined to known
features of genome architecture.
Therefore, we decided to explore the genome archi-
tectural context of RXR signaling, asking the question of
whether RXR signaling is confined by known structural
features of genome organization and/or contributes to
reorganization of these. We determined the cistromes of
CTCF and a member of the cohesin complex (RAD21) in
the absence or presence of ligand-activated RXR. We
found ;30,000 peaks for CTCF and ;24,500 for RAD21
(Supplemental Fig. S1C); the latter showed some in-
crease upon ligand activation. Next, we determined an
overlap of ;12,660 peaks representing similarly high
CTCF and RAD21 occupancy (with peaks having
a MACS2 score >15 and having less than threefold
difference). We considered these as boundaries of func-
tional domains, as suggested by others (Merkenschlager
and Odom 2013; Sofueva et al. 2013). We identified 10,204
such functional domains by pairing the CTCF and RAD21
copeaks with the closest ones with similar scores (Supple-
mental Material).
The median length of such domains was 81.15 kb,
while the average was 149.98 kb. The neighboring do-
mains then were merged into active domains with
<100-kb distances between them. We could designate
almost 700 such domains, which have a median length of
1.1 Mb and an average length of 1.88 Mb. If one overlays
this architectural domain structure with active RXR-
binding sites and regulated genes that we identified (Fig.
5C), one can find that 203 out of the 252 (80%) identified
RXR-regulated genes along with their enhancers fall on
such functional domains. In addition, one can identify
;1113 CTCF genomic binding regions on which RAD21
(cohesin) binding is enhanced and 128 regions on which
RAD21 binding is reduced upon RXR ligand treatment
(Fig. 6A, left). Moreover, RAD21 (cohesin) binding is more
enhanced on active RXR enhancers (GRO-seq+ ones)
when compared with nonactive ones (GRO-seq ones)
(Fig. 6A, middle and right). Importantly, 40% (84 out of
203) of regulated genes have induced RAD21 on their
enhancer and/or CTCF-binding sites. Collectively, these
data suggest that most if not all RXR enhancers act inside
functional domains and that activation of the receptor
contributes to formation of such domains by stabilizing
the genomic architecture and, in some cases, even in-
ducing the binding of enhancers to promoters. Next, we
validated molecularly the interactions in such functional
domains and the impact of ligand on these for long-range
enhancers of Abcg1, Vegfa, and Tgm2 using RT-qPCR-
based 3C (Fig. 6B). These data clearly documented that
the enhancers identified by the combination of RNA-seq,
ChIP-seq, and GRO-seq act in functional domains, loop to
the promoter, and can be readily functionally validated
using transient transfection and 3C as well.
Finally, we asked the question of whether any of these
enhancers communicate with other cis-regulatory ele-
ments or functional domains in the genome. Thus, we
carried out 3C-seq using pairs of baits located in or close
to these regions. We could detect proximal and also long-
range interactions (for details of the analyses, see the
Supplemental Material). At the Vegfa locus, we could
detect interactions between the distant enhancer and the
neighboring enhancers as well as the intronic region with
remarkable specificity (Fig. 6C). Similar results were
obtained in the case of the Tgm2 and Abcg1 loci (Supple-
mental Fig. S7A,B). Importantly, we also detected in-
terchromosomal interactions with much less frequency
(at least 50-fold less) though. In order to provide statistical
context to these findings, we compared the interaction
frequency of a given bait with inactive topological do-
mains, active domains devoid of RXR-regulated regions,
and active domainswith RXR-regulated regions. As shown
in Figure 6D in the case of Abcg1 and Vegfa, there is
significant difference between the frequencies of such
interactions. Similar results were obtained with additional
enhancer of these and the Tgm2 gene. This suggests that
active RXR enhancers interact with other active genomic
regions and with an even higher likelihood with other
RXR-regulated ones. These formally suggest that the
active RXR enhancers form an interchromosomal hub or
network.
Determination of the impact of RXR activation
on the angiogenic capacity of macrophages
Finally, we wanted to see whether some of the identified
novel transcriptional pathways could be validated biolog-
ically. The functional annotation of the genes controlled
by liganded RXR enhancers assigned a large number of
genes into the angiogenesis category (Supplemental Fig.
S4C). These include Vegfa, Hbegf, Litaf, and Hipk2.
Therefore, we decided to functionally test this activity.
First, we determined the excreted VEGFa protein levels
from cell supernatants (Fig. 7A) using different ligands
and could show that RXR induced this protein, as was
suggested by our gene expression measurements as well
(Supplemental Fig. S5). Using RT-qPCRs, we could show
the RXR requirement using RXRa/b double-knockout
macrophages (Fig. 7B). To test whether activation of RXR
promoted angiogenesis in an in vivo relevant setting,
we performed a chorioallantoic membrane (CAM) assay
using macrophages pretreated with RXR agonist. These
cells showed significantly increased angiogenic activity,
which was not detectable in RXRa/b double-knockout
macrophages (Fig. 7C). These data suggest that RXR ac-
tivation can program macrophages toward a distinct cell-
autonomous angiogenic phenotype (Fig. 7D,E).
Discussion
The ultimate goal of studying the function of a particular
transcription factor is to discern its primary biological
action in the entire genome comprehensively. In princi-
ple, this should be done by defining the genomic binding
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Figure 6. Functional characterization of short- and long-range liganded RXR-regulated enhancers. (A) Changing RAD21 peaks in the
presence of 100 nM LG268 on CTCF-binding sites (left) and GRO-seq-positive (middle) and GRO-seq-negative (right) RXR-binding
sites. The log2-normalized read numbers of the significantly changing peaks are plotted. The number of changing peaks and the
statistical stringency applied are indicated below each plot. (B) 3C-RT-qPCR measurements in the presence or absence of LG268 on the
Tgm2, Abcg1, and Vegfa loci. Constant primers were designed to the enhancers and are represented by black columns (anchor points).
Red circles represent the enhancers, purple ones are the promoter regions, TSSs are depicted with green, and intronic regions are
highlighted by cyan circles. The mean and 6SD of triplicate determinations are shown. Representative examples are shown for each
locus. (C) Genome browser view of the Vegfa locus containing the proximal interacting regions of the intergenic (B1) and intronic (B2)
baits and the loop predictions generated based on CTCF/RAD21-cobound regions. 3C-seq heat map (green scale) was made as described
in the Supplemental Material. Asterisks show the sites of the specific baits. GRO-seq and ChIP-seq for the indicated factors are shown.
Black arrowheads and gray dashed lines indicate the predicted domain borders. (D) Box plot representation of the distribution of
interaction frequency of Abcg1 B1 enhancer (chr17: 31,172,998–31,173,656) and Vegfa B1 enhancer (chr17: 45,890,060–45,890,829)
determined by 3C-seq. The interchromosomal interactions of these enhancers were determined as described in the Supplemental
Material. The detected interactions were mapped onto 1-Mb fragments covering the mouse genome. Interaction frequency was
determined by expressing the read number per 1 Mb normalized to 1000 reads. Genome regions (inactive, active, and RXR target) were
qualified as described in the Supplemental Material. Unpaired two-tailed t-test analysis was used to determine significant differences.
Asterisk represents significant difference at P < 0.0001.
Liganded RXR’s genomic action
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Figure 7. RXR activation leads to increased angiogenic activity in macrophages. (A) VEGFa protein levels determined from
supernatants of macrophages treated with LG268 for the indicated periods of time determined by ELISA. The mean and 6SD of
triplicate determinations are shown. Asterisk represents significant difference at P < 0.05; n = 3. (B) Vegfa mRNA levels determined
using RT-qPCR in wild-type (WT) and RXRa/b knockout (KO) macrophages. The mean and 6SD of duplicate determinations are
shown. (C) Macrophage angiogenesis activity was determined using CAM assay in the presence or absence of LG268 using wild-type
and RXRa/b knockout macrophages. Representative images (left) and bar chart of quantification (right) are shown. The mean and 6SD
of three biological replicates are shown. Asterisk represents significant difference at P < 0.05; n = 3. (D) The molecular mechanism
through which Vegfa is regulated in macrophages. Vegfa harbors a set of very-long-range enhancers. The enhancers are marked by the
lineage-determining transcription factor PU.1 and are able to recruit RXR presumably as a heterodimer with RAR or in a homodimeric
form. Upon ligand stimulation, P300 is recruited, and eRNA production is highly increased. These elements can get into the close
proximity of the gene promoter by looping, which is enhanced in the presence of the RXR activator (LG268) and leads to increased gene
expression. This regulatory unit is bordered by CTCF/cohesin (RAD21) cobinding, which is thought to contribute to the topological
domain structure of mammalian genomes and stabilizes chromatin loops. (E) Schematic representation of the various nuclear receptor
dimers and their biological significance in macrophages. PPAR/RXR are known to inhibit the inflammatory response upon activation
by either side as a permissive heterodimer, while the LXR/RXR heterodimer regulates inflammatory response, cholesterol metabolism,
and triglyceride biosynthesis. Our results shed light on the effect of putative, permissive, RAR/RXR, or possibly RXR/RXR dimers in
the angiogenesis program of macrophages, most probably through the regulation of Vegfa and/or Hbegf.
Daniel et al.
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regions and determining the genes proximally regulated
in a given cell type. Using computational tools, one can
identify potential RXR-binding sites on the scale of several
times 100,000 in the mouse genome. When all of the
ChIP-seq data available from fat, from liver, and now in
macrophages are combined, the combined number of
genomic regions bound by RXR is a few times 10,000.
Still, in macrophages, the number of genomic regions is
;5200, but the number of regulated genes by liganding the
receptor is a few times 100. This is further complicated by
the fact that primary targets are hard to reliably identify by
simply measuring steady-state mRNA levels. So the
question remains: How can one find the regulated genes
and the linked receptor-bound enhancers? We attempted
to do this by integrating genome-wide analyses.
Integration of genome-wide localization and nascent
RNA production data identifies active enhancers
A key premise of the work presented here is that genome-
wide localization studies, predominantly ChIP-seq exper-
iments, can be intersected with data from nascent RNA
determinations such as GRO-seq time courses, which
then enables one to comprehensively annotate cistromes
and identify active enhancers (Hah et al. 2013; Lam et al.
2013). This relies on the assumption that in vitro (nuclear
run-on) determination of the activity of RNA polymer-
ases (RNAPs) is a reliable indicator of transcriptional
activation. This has been proven in other systems and
leads to the identification of active enhancers in other
cell types (Koch and Andrau 2011; Wang et al. 2011; Bonn
et al. 2012), although systematic comparisons or cross-
validation with other methods such as subcellular RNA
fractionation (Bhatt et al. 2012) has not been done. The
usage of GRO-seq for the determination of direct tran-
scriptional responses has two major advantages: (1) The
dynamics of the nascent RNA levels depends only on the
rate of RNAP activity, and therefore it is matching
the expected time course of a directly regulated gene.
Our data are clearly demonstrating this because known
and established direct target genes (Abca1, Abcg1,
Angptl4, and Tgm2) as well as newly identified ones
(i.e., Vegfa and Hbegf) show an immediate induction
when assessed by GRO-seq rather than a complex, often
delayed one determined by RNA-seq or RT-qPCR (Fig.
3D). (2) Enhancers contain engaged RNAPs, and their
activity can be revealed by GRO-seq in the form of
a typically few-hundred-base-pair-long divergent tran-
script, termed eRNA. The existence of such transcripts
has been shown before (Kim et al. 2010; Wang et al. 2011).
Although the mechanism of their production and role in
transcription is far from being clarified, it can be reason-
ably assumed that they represent active enhancers, as
the presence of an engaged RNAP strongly indicates it.
Furthermore, if the changes of nascent RNA production
(increase or decrease) at these sites show correlation with
the stimulating signal, it is likely to be associated with or
the consequence of the activity of the signal-specific
transcription factor. A key limitation of today’s technology
is the lack of high-throughput validation of the identified
enhancers. Nonetheless, our high rate of success in vali-
dating such enhancers with low-throughput enhancer trap
approaches, 3C-seq and 3C-RT-qPCR, suggests that signal-
specific changes in eRNA production can be used to filter
active enhancers from the general pool of genomic binding
regions. Altogether, this also means that this combined
approach can serve as proof of concept and a model to
tackle similar problems with other signal-specific tran-
scription factors. A remarkable feature of the approach is
that it allowed the identification of active enhancers in
spite of the fact that these represent a fraction of the
binding regions (not more than 10%–15% by using our
stringent criteria), including very-long-range enhancers. It
is also interesting that the enhancers’ distribution relative
to the TSS appears to be rather symmetrical instead of
being much biased to the upstream regions, suggesting
that one needs to look in both directions and also far away
to identify the true enhancer controlling a particular gene
in a given cellular context. A cautionary conclusion of this
study is that it is very likely that many of the enhancers
identified with less comprehensivemethodsmight need to
be revisited.
RXR colocalizes with PU.1 and recruits P300
as a cofactor to its binding sites
Our data showed that RXR has >5200 binding regions in
macrophages. These peaks are likely to be RXRa-bound
because this is the dominant subtype present in macro-
phages. However the used antibody is pan-RXR-specific
and would recognize all three subtypes. Most of these
sites contain nuclear receptor half sites (AGGTCA),
suggesting that the localization of RXR uses nuclear
receptor-mediated direct DNA binding. In addition, two
independent lines of evidence suggest that there is an
intimate relationship between the lineage-determining
factor PU.1 and RXR: (1) 45% of the RXR peaks contain
PU.1 sites, and (2) there is a significant overlap between
RXR and PU.1 cistromes, as more than two out of three of
RXR-binding regions overlap with PU.1 peaks. This is in
agreement with our anticipation based on previous re-
ports by Lazar and colleagues (Lefterova et al. 2010) and
Liu and colleagues (Pott et al. 2012), who suggested that
binding regions for PPARg, a heterodimerization partner
of RXR, colocalizes with PU.1. This finding supports the
pioneering or bookmarking factor concept put forward
by several investigators (for a review see, Zentner and
Scacheri 2012) to explain various interactions and ge-
nome-wide colocalization between lineage-specific and
signal-specific transcription factors, suggesting that the
lineage-specific factor opens up or marks particular re-
gions in the genome, which then allows or even facilitates
the binding of the signal-specific factors. Although the
sequence of events or the mechanisms of such interac-
tions are unknown, our data are fully compatible with
such a scenario. An additional line of evidence support-
ing this is that there is only a 14% overlap between our
RXR-binding regions and the ones found in 3T3L1 cells
differentiating into adipocytes (Nielsen et al. 2008). Our
work further extended these studies and suggests that
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many if not all RXR heterodimers at least in part colo-
calize with PU.1 in macrophages and that upon ligand
treatment, PU.1 is at least partially released and therefore
might not be required for further binding or transcrip-
tional activity.
Another unexpected aspect of the cistromic interac-
tions identified is that P300 binding is dynamically
recruited upon the RXR ligand treatment to most of the
active RXR sites. Two conclusions can be drawn from
these findings: (1) P300 is major cofactor of mediating
transcriptional activity by RXR in BMDMs in the steady
state. (2) Liganded RXR-regulated transcription complexes
use P300 as one and potentially the major cofactor, and
thus P300 is likely to be responsible for the acetylation of
histone H4K5/8. This is consistent with the initially
proposed role for this protein in nuclear receptor signaling
(Chakravarti et al. 1996) and with themore recent findings
(Jin et al. 2011) but also suggests that P300 is likely to be
specific for this signaling pathway in this cell type.
A key issue with signal-specific transcription factors is
whether the signal contributes to the (re)distribution
of the particular transcription factor. In case of the
RXR-containing receptor dimers, the accepted view is
that RXRs bind to the genome in both the absence and
presence of ligand (Boergesen et al. 2012). Our findings
further support this view now by adding a genome-wide
perspective and show that the only effect RXR ligand has
on the genome-wide distribution of the receptor is that
the enrichment on the preformed binding sites increases.
These data obviously have to be interpreted within the
context of ChIP experiments, meaning that the sum of
all binding in all cells is detected in the time frame of
the 40-min cross-linking used. This method does not
allow the construction of a more dynamic and/or higher-
resolution picture of the receptors’ activation and mobil-
ity. Methods using shorter time resolution show a much
more dynamic behavior of the receptor though (Brazda
et al. 2014). Therefore, our interpretation of the data is
that RXRs’ genome-wide localization is determined by its
own DNA-binding capacity, which allows it to find
preformed sites in the genome to which it can bind, and
this is facilitated by additional factors such as a lineage-
specific factor; i.e., PU.1. The increased affinity that is
observed is either the reflection of more cells being
involved in the response or a higher affinity for the
binding site. However, the experimental approaches used
are not able to determine the relative contribution of
these two mechanisms. We also excluded the possibility
that an endogenous ligand plays a major role in directing
RXRs to its genomic binding sites by using an antagonist.
This behavior is in stark contrast to that of steroid hor-
mone receptors such as GR or estrogen receptor (ER),
whose genomic binding is dictated by the addition of ligand
(Carroll et al. 2005; Welboren et al. 2009). As far as the
genome architectural context of the RXR-regulated en-
hancers and the regulated genes are concerned, we could
show that the vast majority of enhancers and their regu-
lated genes are confined to functional domains bordered by
CTCF/cohesin (RAD21) complexes, suggesting that their
activity localized to these loops (Supplemental Fig. S8).
In addition, the rearrangement of such loops is moderately
though but impacted by ligand activation. Curiously
though, our 3C-seq analyses also revealed that the func-
tional domains and the enhancers within them interact
with each other even on different chromosomes. The func-
tional significance of such interactions is not clear but
might suggest the existence of RXR- or partner-specific
transcription foci or factories inside the nucleus.
Characteristics of the liganded RXR-operated
enhancer network
Our data show, as expected, that the two major permis-
sive heterodimers in BMDMs are RXR:LXR and, to
a lesser extent, RXR:PPAR, as shown by the ready
induction of their established target genes, Angptl4,
Abca1, and Abcg1, and the motifs identified within
their RXR peaks being RXR:PPAR-specific (DR1) and
RXR:LXR-specific ones (DR4). However, our analyses
also uncovered a set of regulated genes, including Tgm2,
and novel ones, such as Vegfa and Hbegf, which could
not be induced efficiently by ligands for permissive
heterodimers, only the RXR-selective LG268 or ligands
activating the RAR receptor. This raises the possibility
of the existence of permissive RXR:RAR heterodimers
or a complex regulatory mechanism/enhancer allowing
activation by either RAR or RXR-activating ligands
(Fig. 7D).
Underpinning this complexity, the enhancers identi-
fied for the regulated genes show a large degree of func-
tional versatility and can be grouped into four broad
categories. Cluster A requires the presence of liganded
RXR; another (cluster B) is best activated if both RXR
and one of its partners is expressed; a third (cluster C) is
mediating RXR-specific signaling, provided RXR is
expressed at a significantly higher level than its partners;
and the enhancers in the fourth (cluster D) work with
multiple combinations of dimers (Supplemental Fig. S4).
A further level of complexity is that a given gene (i.e.,
Vegfa or Abca1) has enhancers from more than one
category.
All of these support that RXR has a unique genomic
effect that cannot be recapitulated by any ligand or
combination of ligands. This is mechanistically served
by activation of permissive heterodimers such as LXR:RXR
and PPAR:RXR and activation of enhancers inducible
by RAR as well. In addition, some of the eTranscript
inductions appear to be specific for RXR.
This and the facts that, using our most stringent
criteria, we identified only 226 induced genes, and only
7.4% of the identified binding sites are active enhancers
suggest that activation of RXR is tightly controlled in
this cell type and leads to distinct and selective and not
pleiotropic gene expression. Unexpectedly, a network of
enhancers that could be linked to a set of genes—includ-
ing Vegfa, Hbegf, Hipk2, Litaf, Cxcl2, and Foxo3, which
have been clearly linked to angiogenesis—was also
revealed.
The regulation of Vegfa by RXR is intriguing because it
appears to use a set of very-long-range enhancers (270 kb
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downstream) and shows RXR/RAR specificity, including
RXR ligand-induced looping (Fig. 7D). We presented here
a novel integrated approach to identify functional en-
hancers and link those to primarily regulated genes for
a signal-dependent transcriptional factor, liganded RXR.
This integrated approach revealed that ligand stimulation
of RXR activates only a small fraction of the DNA-bound
molecules confined by CTCF/cohesin-delimited func-
tional domains (Supplemental Fig. S8) and leads to a dis-
tinct gene expression program, which results in increased
angiogenic potential and might be a valid macrophage
reprograming/therapeutic target (Fig. 7E).
Materials and methods
Materials
The following ligands were used: LG268 and LG1208 were gifts
from M. Leibowitz (Ligand Pharmaceuticals), RSG and AM580
were from Sigma, and GW3965 was a gift from T.M. Wilson
(GlaxoSmithKline).
Differentiation of BMDMs
Isolation and differentiation were completed as described earlier
(Barish et al. 2005).
RNA-seq
The RNA-seq library was prepared from two biological replicates
by using a TruSeq RNA sample preparation kit (Illumina)
according to the manufacturer’s protocol. Analysis was carried
out as described in the Supplemental Material.
ChIP
ChIP was performed as previously described (Barish et al. 2010),
with minor modifications. Libraries were prepared by Ovation
Ultralow Library Systems (Nugen) from two biological replicates
according to the manufacturer’s instructions. ChIP-seq analysis
and domain prediction were carried out as described in the
Supplemental Material.
GRO-seq
GRO-seq and library preparation were performed as described
earlier (Core et al. 2008; Hah et al. 2011), with limited modifi-
cations. Libraries were generated from two biological replicates
of BMDMs treated with 100 nM LG268. Analysis was carried out
as described in the Supplemental Material.
RT-qPCR
RNA was isolated with Trizol reagent (Molecular Research
Center). RNA was reverse-transcribed with Tetro reverse tran-
scriptase (Bioline). Transcript quantification was performed by
RT-qPCR reaction using SYBR Green dye (Diagenode). Tran-
script levels were normalized to Ppia or Rplp0.
3C
3C experiments were completed as described previously with
minor modifications (Miele et al. 2006). The detailed protocol is
available in the Supplemental Material.
3C-seq
Experimentswere carried out as previously described (Stadhouders
et al. 2013). For details, see the Supplemental Material.
Transient transfection
Enhancer sequences were PCR-amplified from a BAC or genomic
DNA and cloned into pUC18 HSV TK-LUC. Transient trans-
fections were carried out as previously described (Szanto et al.
2010).
ELISA
ELISA experiments were carried out according to the manufac-
turer’s instructions (R&D Systems).
CAM assay
CAM assays were performed as described previously (Movahedi
et al. 2008). The detailed protocol is presented in the Supple-
mental Material.
Data access
Sequencing data were submitted to Sequence Read Archive
under accession number SRP019970.
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